BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 18537153)

  • 1. Dihydropyrimidine dehydrogenases and cytidine-deaminase gene polymorphisms as outcome predictors in resected gastric cancer patients treated with fluoropyrimidine adjuvant chemotherapy.
    Grau JJ; Caballero M; Monzó M; Muñoz-García C; Domingo-Domenech J; Navarro A; Conill C; Campayo M; Bombí JA
    J Surg Oncol; 2008 Aug; 98(2):130-4. PubMed ID: 18537153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
    Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
    Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of adjuvant chemotherapy in the long-term outcome of patients with resected gastric cancer.
    Grau JJ; Martín M; Fuster J; Pera M; García-Valdecasas JC; Bombí JA; Bordas JM; Alcobendas F; Grande L; Estapé J
    J Surg Oncol; 2003 Apr; 82(4):234-40. PubMed ID: 12672007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CyclinD1 and interleukin-1 receptor antagonist polymorphisms are associated with prognosis in neoadjuvant-treated gastric carcinoma.
    Stocker G; Ott K; Henningsen N; Becker K; Hapfelmeier A; Lordick F; Hois S; Plaschke S; Höfler H; Keller G
    Eur J Cancer; 2009 Dec; 45(18):3326-35. PubMed ID: 19822419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15-year follow-up study at a single korean institute.
    Moon YW; Jeung HC; Rha SY; Yoo NC; Roh JK; Noh SH; Kim BS; Chung HC
    Ann Surg Oncol; 2007 Oct; 14(10):2730-7. PubMed ID: 17632757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population.
    Huang ZH; Hua D; Li LH
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):911-8. PubMed ID: 18704422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of adjuvant chemoradiotherapy after a radical gastrectomy and a D2 node dissection for gastric adenocarcinoma.
    Leong CN; Chung HT; Lee KM; Shakespeare TP; Mukherjee RK; Wong LC; Lu JJ; Tey J; Lim R; So JB; Back MF
    Cancer J; 2008; 14(4):269-75. PubMed ID: 18677137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does graded histologic response after neoadjuvant chemotherapy predict survival for completely resected gastric cancer?
    Mansour JC; Tang L; Shah M; Bentrem D; Klimstra DS; Gonen M; Kelsen DP; Brennan MF; Coit DG
    Ann Surg Oncol; 2007 Dec; 14(12):3412-8. PubMed ID: 17909917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of dihydropyrimidine dehydrogenase in cancer cells but not in stromal cells predicts the efficacy of fluorouracil treatment in patients with gastric carcinoma.
    Hisamitsu K; Tsujitani S; Yamaguchi K; Fukuda K; Konishi I; Kaibara N
    Anticancer Res; 2004; 24(4):2495-501. PubMed ID: 15330204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The expression profiles of orotate phosphoribosyltransferase and dihydropyrimidine dehydrogenase in gastric cancer and their clinical significance.
    Oeda M; Yoshida K; Sanada Y; Wada Y; Suzuki T; Mizuiri H; Konishi K; Shigematsu H; Tanabe K; Fukushima M
    Oncol Rep; 2006 Dec; 16(6):1165-72. PubMed ID: 17089033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High intratumoral dihydropyrimidine dehydrogenase mRNA levels in pancreatic cancer associated with a high rate of response to S-1.
    Kuramochi H; Hayashi K; Uchida K; Nakajima G; Hatori T; Danenberg KD; Danenberg PV; Yamamoto M
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):85-9. PubMed ID: 18309485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of large intragenic rearrangements in dihydropyrimidine dehydrogenase (DPYD) gene in fluoropyrimidine-treated patients with high-grade toxicity.
    Ticha I; Kleiblova P; Fidlerova J; Novotny J; Pohlreich P; Kleibl Z
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):615-8. PubMed ID: 19288105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic role of interleukin-1beta gene and interleukin-1 receptor antagonist gene polymorphisms in patients with advanced gastric cancer.
    Graziano F; Ruzzo A; Santini D; Humar B; Tonini G; Catalano V; Berardi R; Pizzagalli F; Arduini F; Bearzi I; Scartozzi M; Cascinu S; Testa E; Ficarelli R; Magnani M
    J Clin Oncol; 2005 Apr; 23(10):2339-45. PubMed ID: 15800325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy.
    Huang ZH; Hua D; Du X
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):1001-7. PubMed ID: 19247656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity.
    Ezzeldin H; Johnson MR; Okamoto Y; Diasio R
    Clin Cancer Res; 2003 Aug; 9(8):3021-8. PubMed ID: 12912951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy.
    Amstutz U; Farese S; Aebi S; Largiadèr CR
    J Exp Clin Cancer Res; 2008 Oct; 27(1):54. PubMed ID: 18937829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perineural invasion after preoperative chemotherapy predicts poor survival in patients with locally advanced gastric cancer: gene expression analysis with pathologic validation.
    Jhawer M; Coit D; Brennan M; Qin LX; Gonen M; Klimstra D; Tang L; Kelsen DP; Shah MA
    Am J Clin Oncol; 2009 Aug; 32(4):356-62. PubMed ID: 19381079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detailed analysis of five mutations in dihydropyrimidine dehydrogenase detected in cancer patients with 5-fluorouracil-related side effects.
    Gross E; Ullrich T; Seck K; Mueller V; de Wit M; von Schilling C; Meindl A; Schmitt M; Kiechle M
    Hum Mutat; 2003 Dec; 22(6):498. PubMed ID: 14635116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients.
    Ezzeldin HH; Lee AM; Mattison LK; Diasio RB
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8699-705. PubMed ID: 16361556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Severe bone marrow suppression during adjuvant chemotherapy for gastric cancer by S-1 and its possible relationship to dihydropyrimidine dehydrogenase deficiency].
    Aragane H; Suchi K; Shimomura M; Katano T; Yasui H; Kan K
    Gan To Kagaku Ryoho; 2010 Jan; 37(1):131-3. PubMed ID: 20087047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.